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Abstract 
No meta-analysis in the field of depression has examined the effects of 
combined treatment compared with pill placebo, nor has any meta-analysis 
integrated the comparison of combined treatment against pharmacotherapy 
alone and psychotherapy alone (i.e., mono treatments). In this 
comprehensive meta-analysis, we found that combined treatment had a 
moderate effect on depression compared with pill placebo (g=0.46), and 
small to moderate effects compared against pharmacotherapy (g=0.38) 
alone, psychotherapy (g=0.34) alone, and psychotherapy plus placebo 
(g=0.23). There were some indications for publication bias when combined 
therapy was compared against placebo (adjusted effect size g=0.31). In 
multivariate metaregression analyses we found no significant differential 
predictors for the four comparisons. There were some indications that the 
use of interpersonal psychotherapy in the combined treatment was 
associated with a smaller effect size, but this has to be considered with 
caution, because of the correlational nature of this association. Despite 
limitations (small number of studies; suboptimal quality of studies) this 
meta-analysis suggests that combined treatment of depression may be the 
best treatment available for adult depression, and that it is significantly 
more effective than placebo, pharmacotherapy alone, psychotherapy alone 
and the combination of psychotherapy and placebo. 
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Introduction 
  
It is well-established that psychological and pharmacological therapies 
are effective in the treatment of adult depression. Several types of psychotherapy 
have been shown to be effective, including cognitive behavior therapy (Gloaguen, 
Cottraux, Cucherat, & Blackburn, 1998; Cuijpers, Berking, Andersson, Quigley, 
Kleiboer, & Dobson, 2013), interpersonal psychotherapy (Cuijpers, Geraedts, van 
Oppen, Andersson, Markowitz, & van Straten, 2011), behavioral activation 
therapy (Ekers, Richards, & Gilbody, 2008), problem-solving therapy (Malouff, 
Thorsteinsson, & Schutte, 2007), counseling (Cuijpers, Driessen, Hollon, van 
Oppen, Barth, & Andersson, 2012), and possibly psychodynamic therapy 
(Shedler, 2010). Dozens of trials directly comparing different types of 
psychotherapy have also shown that there are no or only small differences 
between the effects of these therapies and that all therapies seem to be about 
equally effective. In addition, guided self-help treatments including internet-based 
treatment (Cuijpers, Donker, van Straten, & Andersson, 2010; Andersson, & 
Cuijpers, 2009) and group treatments (Cuijpers, van Straten, & Warmerdam, 
2008) appear to be as effective as face-to-face treatments with one therapist and 
one patient. Several types of antidepressant medications have also been found to 
be effective, including tricyclic antidepressants, SSRIs and several others (Bauer, 
Pfennig, Severus, Whybrow, Angst, Möller, et al., 2013). Several hundreds of 
trials directly comparing different types of medication have also shown that all 
these medications are most likely about equally effective (Gartlehner, Hansen, 
Morgan, Thaler, Lux, Van Noord, et al., 2012). In addition, dozens of direct 
comparisons between psychotherapies and pharmacotherapies have shown that 
psychotherapies and pharmacotherapies are also equally effective or 
approximately equally effective (Cuijpers, Sijbrandij, Koole, Andersson, 
Beekman, & Reynolds, 2013). This suggests that all psychological and 
pharmacological treatments of adult depression are equally effective or about 
equally effective for mild to moderate depression, although this may not pertains 
to more chronic forms of depression and dysthymia (Cuijpers, van Straten, 
Schuurmans, van Oppen, Hollon, & Andersson, 2010). 
The combination of psychotherapy and pharmacotherapy, however, has 
been shown to be more effective then pharmacotherapy alone (de Maat, Dekker, 
Schoevers, & de Jonghe, 2007; Cuijpers et al., 2014), psychotherapy alone 
(Pampallona, Bollini, Tibaldi, Kupelnick, & Munizza, 2004), and the combination 
of psychotherapy and placebo (Cuijpers, Turner, Mohr, Hofmann, Andersson, 
Berking, et al., 2011). Combined treatment seems to be, therefore, the most 
effective treatment currently available for adult depression.  
The mechanisms behind the added effect of combining treatments is 
largely unknown. One possible mechanism would be that different patients 
respond to different treatments and hence providing two treatments would result 
in more patients improving. However, it is also possible that the two treatment 
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formats (for simplicity we here assume that pharmacotherapy and psychotherapy 
are two separate forms of treatments bearing in mind that there are different forms 
of both pharmacotherapy and psychotherapy) interact. An example of this could 
be if a patient gets initial help from the psychotherapy, then additional boost from 
medication, and then additional help from the skills and insights gained in 
psychotherapy. However, placebo effects appear to ubiquous in depression 
treatments in particular when there is contact with the study coordinators 
(Posternak & Zimmerman, 2007),  and hence there is a need to elucidate how well 
combined treatment works against placebo only and indeed also single treatments. 
No meta-analysis has examined the effects of combined treatment against 
pill placebo only. As mentioned earlier, there have been meta-analyses in which 
combined treatment was compared with pharmacotherapy alone and with 
psychotherapy alone (De Maat et al., 2007; Cuijpers et al., 2014; Pampanolla et 
al., 2004), but no meta-analysis has examined all studies in which combined 
treatment was compared with any other treatment or placebo. We think this is 
important to examine further, not only because combined treatment may be the 
most effective treatment currently available, but also because the comparative 
effects of combined treatment versus pharmacotherapy and those of combined 
treatment versus psychotherapy have not yet been compared with each other. 
Combined treatment has been shown to be more effective than pharmacotherapy 
and psychotherapy alone, but whether these differences are comparable has never 
been examined in meta-analytic research. 
We decided therefore to conduct a comprehensive meta-analysis in which 
combined treatment was compared with placebo-only, with psychotherapy, with 
pharmacotherapy and with the combination of psychotherapy and placebo. 
  
Methods 
  
Identification and selection of studies 
We used a database of papers on the psychological treatment of 
depression that has been described in detail elsewhere (Cuijpers, van Straten, 
Warmerdam, & Andersson, 2008), and that has been used in a series of earlier 
published meta-analyses (www.evidencebasedpsychotherapies.org). This database 
has been continuously updated through comprehensive literature searches (from 
1966 to January 2014). In these searches, we examined 14,164 abstracts from 
Pubmed (3,638 abstracts), PsycInfo (2,824), Embase (4,682) and the Cochrane 
Central Register of Controlled Trials (3,020). These abstracts were identified by 
combining terms indicative of psychological treatment and depression (both 
MeSH terms and text words). For this database, we also checked the primary 
studies from earlier meta-analyses of psychological treatment for depression to 
ensure that no published studies were missed. From the 14,164 abstracts (10,474 
after removal of duplicates), we retrieved 1,476 full-text papers for possible 
inclusion in the database. 
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We included (1) randomized controlled trials (2) in adults with a 
depressive disorder, in which (3) a combined treatment (consisting of a 
psychological and a pharmacological intervention) (4) was compared to (a) a pill 
placebo only control condition, (b) pharmacotherapy only, (c) psychotherapy 
only, (d) or a psychotherapy plus pill placebo condition.  
Depression could be defined as major depressive disorder or unipolar 
mood disorder (including dysthymia), according to a diagnostic interview (such as 
the DISC, CIDI, or SCAN), or as clinically relevant depressive symptoms 
according to a score above a cut-off on a depression rating scale. We excluded 
studies in inpatients, in children and adolescents (< 18 years). Comorbid general 
medical or psychiatric disorders were not used as an exclusion criterion. No 
language restrictions were applied, except for Chinese. 
  
Quality assessment and data extraction 
We assessed the validity of included studies using four of the six criteria 
of the ‘Risk of bias’ assessment tool, developed by the Cochrane Collaboration 
(Higgins & Green, 2008). This tool assesses possible sources of bias in 
randomized trials, including the adequate generation of allocation sequence; the 
concealment of allocation to conditions; the prevention of knowledge of the 
allocated intervention (masking of assessors); and dealing with incomplete 
outcome data (this was assessed as positive when intention-to-treat analyses were 
conducted, meaning that all randomized patients were included in the analyses).  
We also coded additional aspects of the included studies, including 
participant characteristics (recruitment method: community, from clinical 
samples, or other; target group: adults in general, or more specific target groups 
such as older adults), psychotherapy characteristics (format: individual, group, or 
guided self-help; number of sessions; and type of psychotherapy: cognitive 
behavior therapy, interpersonal psychotherapy, or other type); type 
pharmacotherapy (SSRI, TCA, other), and study characteristics (type of 
comparison: placebo, pharmacotherapy, psychotherapy, psychotherapy plus 
placebo; and country: US, UK, Europe, other).  
  
Meta-analyses 
For each comparison between a combined treatment and one of the 
comparison groups, the effect size indicating the difference between the two 
groups at post-test was calculated (Hedges's g). Effect sizes were calculated by 
subtracting (at post-test) the average score of the combined treatment group from 
the average score of the control group, and dividing the result by the pooled 
standard deviation. Because several studies had relatively small sample sizes, we 
corrected the effect size for small sample bias according to the procedures 
suggested by Hedges and Olkin (1985).  
In the calculations of effect sizes, we used only those instruments that 
explicitly measured symptoms of depression, such as the HAM-D (Hamilton, 
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1960), or the Beck Depression Inventory (Beck, Ward, Mendelson, Mock, & 
Erbaugh, 1961). If more than one depression measure was used, the mean of the 
effect sizes was calculated, so that each comparison yielded only one effect. If 
dichotomous outcomes were reported without means and standard deviations, we 
used the procedures of the Comprehensive Meta-Analysis software (version 
2.2.021) (see below) to calculate the standardized mean difference.  
To calculate pooled mean effect sizes, we used the computer program 
Comprehensive Meta-Analysis. Because we expected considerable heterogeneity 
among the studies, we employed a random effects pooling model in all analyses.  
Because the standardized mean difference (Hedges’ g) is not easy to 
interpret from a clinical perspective, we transformed these values into the 
number-needed-to-treated (NNT), using the formulae provided by Kraemer and 
Kupfer (2006). The NNT indicates the number of patients that have to be treated 
in order to generate one additional positive outcome (Laupacis, Sackett, & 
Roberts, 1988). 
As a test of homogeneity of effect sizes, we calculated the I2-statistic as 
an indicator of heterogeneity in percentages. A value of 0% indicates no observed 
heterogeneity, and larger values indicate increasing heterogeneity, with 25% as 
low, 50% as moderate, and 75% as high heterogeneity. We calculated 95% 
confidence intervals around I2 (Ioannidis, Patsopoulos, & Evangelou, 2007), using 
the non-central chi-squared-based approach within the heterogi module for Stata 
(Orsini, Higgins, Bottai, & Buchan, 2005). We also calculated the Q-statistic, but 
only report whether this was significant. 
Subgroup analyses were conducted according to the mixed effects model 
(Borenstein, Hedges, Higgins, & Rothstein, 2009), in which studies within 
subgroups are pooled with the random effects model, while tests for significant 
differences between subgroups are conducted with the fixed effects model. For 
continuous variables, we used meta-regression analyses to test whether there was 
a significant relationship between the continuous variable and effect size, as 
indicated by a Z-value and an associated p-value. 
Multivariate meta-regression analyses in which more than one predictor 
was entered simultaneously were conducted in STATA/MP 11.0 for Mac, because 
these analyses cannot be conducted in Comprehensive Meta-analysis. In order to 
avoid collinearity, we first calculated the correlation between predictors but found 
no correlation higher than r = 0.50. 
Publication bias was tested by inspecting the funnel plot on primary 
outcome measures and by Duval and Tweedie’s trim and fill procedure (2000), 
which yields an estimate of the effect size after the publication bias has been 
taken into account (Borenstein et al., 2009). We also conducted Egger’s test of the 
intercept to quantify the bias captured by the funnel plot and test whether it was 
significant.  
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Results 
  
Selection and inclusion of studies 
After examining a total of 14,902 abstracts (10,992 after removal of 
duplicates), we retrieved 1,613 full-text papers for further consideration. We 
excluded 1,560 of the retrieved papers. The flowchart describing the inclusion 
process, including the reasons for exclusion, is presented in Figure 1. A total of 53 
studies met inclusion criteria.  
  
 
 
Figure 1. Flowchart of inclusion of studies 
 
Characteristics of included studies 
The 53 studies included 4,740 participants, 182 in the placebo-only 
groups (6 comparisons), 1585 in the pharmacotherapy groups (41 comparisons), 
731 in the psychotherapy groups (19 comparisons), and 427 in the psychotherapy 
plus placebo groups (17 comparisons).  
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Table 1. Selected characteristics of studies comparing combined treatment with placebo, 
pharmacotherapy, psychotherapy and psychotherapy plus placebo (N=53). 
  
 Compa-
risons a) 
Recruit-
ment 
Target 
group 
Depression Psy Type Format Nses Medica-
tion 
Quality b) C 
Appleby, 1997 PH PL PP Other PPD Mood CBT Ind 6 SSRI + – + + UK 
Beck, 1985 PS Comm Adults Mood CBT Ind 20 TCA – – – – US 
Bellack, 1981 PH PP Comm Adults Mood Other Ind 12 TCA – – + – US 
Bellino, 2006 PH Clin Borderline MDD IPT Ind 16 SSRI – – + – EU 
Blackburn, 1981 PH PS Clin Adults MDD CBT Grp 15 TCA – – – – US 
Bloch, 2012 PP Other PPD MDD Dynamic ind 12 SSRI + + + + ISR 
Blom, 2007 PH PS PP Clin Adults MDD IPT Ind 12 Snri – – + + EU 
Browne, 2002 PH PS Comm Adults Mood IPT Ind 10 SSRI + + + – CA 
Burnand, 2002  PH Clin Adults MDD Dynamic Ind 10 TCA – – + – EU 
De Jonghe, 2001 PH Clin Adults MDD Dynamic Ind 16 Other – – + + EU 
De Jonghe, 2004 PS Clin Adults MDD Dynamic Ind 16 Other – – + – EU 
De Mello, 2001 PH Clin Adults Mood IPT Ind 16 Rima – – + – BR 
Denton, 2012 PH Comm Adults MDD Other Ind 15 Other + + + + US 
Dozois, 2009 PH Clin Adults MDD CBT Ind 15 Other – + – – CA 
Finkelzeller, 2009 PH PS Other Medical MDD IPT Grp 12 SSRI + – + + EU 
Friedman, 1975  PH PL PP Clin Adults Other Other Ind 12 TCA – – + – US 
Hautzinger, 1996 PH PS Clin Adults Mood CBT Ind 24 TCA – – + + EU 
Hellerstein, 2001 PH Clin Adults Mood Other Grp 16 SSRI – – – + US 
Hernandez, 2004 PP Comm Alcohol MDD SUP Ind 8 SNRI – – + + US 
Hollon, 1992 PH PS Clin Adults MDD CBT Ind 20 TCA – – + + US 
Hsiao, 2011 PH Clin Adults MDD Other Ind 8 Other + – + + TW 
Keller, 2000 PH PS Clin Adults Mood Other Ind 18 SNRI + + + + US 
Lam, 2013 PH Comm Adults MDD CBT Ind 8 SSRI + + + + CA 
Lesperance, 2007 PH PL PP Comm Medical MDD IPT Ind 12 SSRI + + + + CA 
Lynch, 2007 PH Clin Person dis Other Other Grp 28 Other – – – – US 
Macaskil, 1996 PH Clin Adults MDD CBT Ind 30 TCA – – – – UK 
Maina, 2010 PH Clin Ocd MDD Dynamic Ind 13 SSRI + + + + EU 
Maldonado 1984a PH Clin Adults Mood CBT/SST Ind 10 Other – – + – EU 
Markowitz, 1998   PS Comm Medical Other SUP Ind 16 TCA + + + + US 
Markowitz, 2005 PH PS Comm Adults Mood IPT Ind 17 SSRI + + + + US 
McGrath, 1996 PP Comm Alcohol Mood Other Ind 12 TCA – – – + US 
Misri, 2004 PH Clin PPD Mood CBT Ind 12 SSRI + – + + CA 
Mitchell, 2009 PH Other Medical Other Other Ind 9 Other + + + + US 
Moak, 2003 PP Comm Alcohol Other CBT Ind 12 SSRI – – – + US 
Murphy, 1984 PH PS PP Clin Adults MDD CBT Ind 20 TCA + + – + US 
Mynors, 2000      PS PH Clin Adults MDD PST Ind 6 SSRI + + + + UK 
Naeem, 2011 PH Clin Adults MDD CBT Ind 9 SSRI + + + + PA 
Ravindran, 1999 PH PL PP Comm Adults Mood CBT Grp 12 SSRI + + + – CA 
Reynolds, 1999 PH PL PP Comm Elderly MDD IPT Ind 16 TCA – – + + US 
Roth, 1982 PS Comm Adults MDD Other Grp 12 TCA – – – – US 
Rush, 1981 PS nr Adults MDD CBT Ind 20 TCA – – + + US 
Schiffer, 1990 PP Other Medical MDD Other Ind 5 TCA – – – – US 
Shamsaei, 2008     PH PS Clin Adults MDD CBT Ind 8 SSRI + – + – IR 
Sirey, 2005 PH Clin Elderly MDD Other Ind 5 Other – – + + US 
Stravynsky, 1994  PS Clin Adults MDD CBT Grp 12 TCA – – + – CA 
Targ, 1994 PP Comm Medical Mood Other Grp 12 SSRI – – + – US 
Thompson, 2001   PH PS Comm Elderly MDD CBT Ind 18 TCA – – – + US 
Weissman, 1979 PH PS Clin Adults MDD IPT Ind 16 TCA – – + – US 
Wiles, 2008 PH Other Adults Mood CBT Ind 16 Other + + + + UK 
Wiles, 2013 PH Clin Adults MDD CBT Ind 12 Other + + + + UK 
Wilson, 1982  PH PL PP Comm Adults Other BA Ind 7 TCA – – + – AU 
Yang, 2009 PP Clin Adults MDD Other Grp 8 SSRI + – + + TW 
Zisook, 1998 PP Clin Medical MDD SUP Grp 8 SSRI – – + + US 
  
a) This column indicates the comparisons that are examined in the studies. PH: combined versus 
pharmacotherapy; PS: combined versus psychotherapy; PP: combined versus psychotherapy plus 
placebo; PL: combined versus placebo. 
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Table 1 (continued). Selected characteristics of studies comparing combined treatment 
with placebo, pharmacotherapy, psychotherapy and psychotherapy plus placebo (N=53). 
 
b) In this column a positive or negative sign is given for four quality criteria, respectively: allocation 
sequence; concealment of allocation to conditions; blinding of assessors; and intention-to-treat 
analyses. 
  
Abbreviations: AU: Australia; BA: behavioral activation therapy; BR: Brasil; CA: Canada; CBT: 
cognitive behavior therapy; Clin: recruitment from clinical samples; Comm: community 
recruitment; Dynamic: dynamic therapy; EU: Europe; Grp: group; Ind: individual; IPT: 
interpersonal psychotherapy; IR: Iran; ISR: Israel; MDD: major depressive disorder; Mood: mood 
disorder; Nses: number of therapy sessions; PA: Pakistan; Person dis: personality disorder; PH: 
Combined versus pharmacotherapy; PL: Combined versus placebo; PP: Combined versus 
psychotherapy plus placebo; PPD: postpartum depression; PS: Combined versus psychotherapy; 
PST: problem-solving therapy; Psy type: type of psychotherapy; Rima: Reversible Monoamino-
oxidase inhibitors; SNRI: Serotonin-noradrenalin Reuptake Inhibitors; SSRI: Selective Serotonin 
Reuptake Inhibitors; SST: social skills training; SUP: supportive therapy; TCA: Tricyclic 
antidepressants; TW: Taiwan; UK: United Kingdom; US: United States. 
 
Selected characteristics of the included studies are presented in Table 1. 
Most studies (34) were aimed at adults in general, the other studies (19) were 
aimed at more specific target groups (patients with comorbid alcohol problems, 
with medical problems, comorbid personality disorders, OCD, or postpartum 
depression). Most studies (29) recruited only from clinical samples, while the 
other studies also recruited through the community (17), or used other recruitment 
strategies, such as systematic screening (7). 
Most studies examined cognitive behavior therapy (CBT) (19), or 
interpersonal psychotherapy (IPT) (9), in an individual treatment format (43). 
SSRIs (19 studies) and TCAs (19) were used in most studies as medications; the 
other studies either used another type of medication (such as SNRI) (4), or used a 
medication protocol (11). Most studies were conducted in the US (25), or Europe 
(14). 
The quality of the included studies varied (Table 1). Twenty-two of the 53 
studies reported an adequate sequence generation. Seventeen studies reported 
allocation to conditions by an independent (third) party. Forty-one studies 
reported blinding of outcome assessors and in 32 studies intention-to-treat 
analyses were conducted. Thirteen studies met all four quality criteria, 18 met 2 or 
3 criteria; and the remaining 22 studies had a lower quality (0 or 1 of the four 
criteria). 
  
Overall effects of combined treatment compared with placebo, psychotherapy and 
pharmacotherapy 
The effects of combined treatment compared with placebo only was g = 0.46 
(95% CI: 0.21~0.70), which corresponds with a NNT of 3.91 (Table 2). 
Heterogeneity was low (I2=17), although the confidence intervals around this 
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were broad (95% CI: 0~62). Because of the small number of studies we did not 
conduct any additional analyses. 
 
Table 2. Effects of combined treatment of adult depression compared with 
pharmacotherapy, psychotherapy, psychotherapy + placebo, and with placebo only: 
Hedges’ g a). 
  
  Ncomp g 95% CI I2 95% CI NNT 
Combined treatment vs. placebo       
All studies  6 0.46 0.21~0.70 17 0~62 3.91 
        
Combined treatment vs. pharmacotherapy       
All studies  41 0.38 0.26~0.49 51 29~66 4.72 
4 outliers removed b)  37 0.34 0.25~0.44 18 0~46 5.26 
HAMD only  22 0.28 0.11~0.44 56 30~73 6.41 
BDI only   13 0.41 0.28~0.54 0 0~57 4.39 
        
Combined treatment vs. psychotherapy       
All studies  19 0.34 0.20~0.48 31 0~60 5.26 
One outlier removed c) 18 0.33 0.23~0.43 0 0~50 5.43 
HAMD only  13 0.24 0.10~0.39 26 0~61 7.46 
BDI only  11 0.39 0.13~0.65 54 10~77 4.59 
        
Combined treatment vs. psychotherapy + 
placebo 
      
All studies  17 0.23 0.06~0.40 27 0~59 7.69 
One outlier removed d)  16 0.27 0.13~0.41 0 0~52 6.58 
HAMD only  9 0.33 -0.03~0.69 74 50~87 5.43 
BDI only  5 0.13 -0.14~0.40 0 0~79 13.51 
  
*: p<0.05 **: p<0.01 ***: p<0.001  
Abbreviations: CI: Confidence interval; Ncomp: number of comparisons; NNT: Numbers-needed-to-
treat. 
a) according to the random effects model; b) Naeem et al., 2011; Mitchell et al., 2009, Maldonado-
Lopez et al., 1984; Browne et al., 2002; c) Shamshei et al., 2008; d) Bellack, 1981 
 
The effect size indicating the difference between combined treatment and 
pharmacotherapy only was g = 0.38 (95% CI: 0.26~0.49; NNT=4.72). 
Heterogeneity was moderate (I2=51), but dropped to low (I2=18) after removal of 
4 possible outliers. Outliers were defined as studies of which the 95% CI around 
the effect size did not overlap with the effect size of the pooled studies together.  
The difference between combined treatment and psychotherapy only was 
comparable to those of combined versus pharmacotherapy (g = 0.34; 95%  
CI: 0.20~0.48; NNT=5.26). The already low level of heterogeneity in the main 
analyses dropped to zero after removal of one outlier. 
The effects of combined treatment versus psychotherapy plus placebo, 
indicating the contribution of active medication to the effects of combined 
treatment, was somewhat smaller (g = 0.23; 95% CI: 0.06~0.40; NNT=7.69), with 
low to zero heterogeneity (I2=27). 
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 Study g 95% CI p g (95% CI) 
Appleby, 1997 0,93 0,32~1,54 0,00 
Friedman, 1975  0,38 -0,09~0,86 0,12 
Lesperance, 2007 0,22 -0,12~0,56 0,20 
Ravindran, 1999 0,86 0,19~1,52 0,01 
Reynolds, 1999 0,52 -0,20~1,25 0,16 
Wilson, 1982  0,21 -0,56~0,99 0,59 
 0,46 0,21~0,70 0,00 
           0.5         1.0 
 
Figure 2. Standardized effect sizes of combined pharmacotherapy and psychotherapy for 
adult depression compared with pill placebo: Hedges’ g. 
 
Publication bias 
We examined publication bias in these four main comparisons. We found 
some indications for possible publication bias according to Duvall and Tweedie’s 
trim and fill procedure in the combined versus placebo conditions (number of 
imputed studies = 2; adjusted effect size g = 0.31; 95% CI: 0.01~0.60), but not 
according to Egger’s test (p = 0.11). The same was true for the combined versus 
pharmacotherapy conditions (number of imputed studies = 2; adjusted effect size 
g = 0.28; 95% CI: 0.14~0.41; Egger’s test p = 0.16). In the combined versus 
psychotherapy conditions and in the combined versus psychotherapy plus placebo 
neither Duvall and Tweedie’s procedure nor Egger’s test resulted in indications 
for publication bias (number of imputed studies = 0; Egger’s test p > 0.1). 
  
Subgroup and metaregression analyses 
We conducted a series of subgroup analyses to examine the association of 
the effect sizes with possible moderators. Because of the small number of studies 
in the combined versus placebo comparisons, we did not conduct subgroup 
analyses for this comparison. For the other three comparisons (combined versus 
pharmacotherapy, versus psychotherapy, versus psychotherapy plus placebo) we 
examined whether the following moderators: target group (adults in general 
versus more specific target group), baseline severity (lower than 17 on the HAM-
D; 17 to 23; 24 or higher), psychotherapy type (CBT; IPT; other), treatment 
format (individual versus group), type of medication (SSRI; TCA; other), and 
quality (met 3 or 4 criteria on the Cochrane risk of bias assessment tool versus 0 
to 2 criteria). As can be seen in Table 3, we found only one significant subgroup: 
in the combined versus pharmacotherapy condition, the effect size was 
significantly smaller when SSRIs were given as medications, compared with 
TCAs and other medications. In the same comparison, there was a trend (p < 0.1) 
suggesting that the effect size may be smaller when IPT was used as 
psychological treatment, compared with CBT and other psychotherapies. 
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Table 3. Effects of .combined treatment of adult depression compared with 
pharmacotherapy, psychotherapy, psychotherapy + placebo: Subgroup analyses a) b) . 
  
  Ncomp g 95% CI I2 95% CI p NNT 
 
Combined treatment vs. pharmacotherapy 
       
Target group Adults in general 29 0.39 0.24~0.53 48 20~66 0.82  
 More specific 12 0.36 0.14~0.58 59 23~78   
Baseline severity c) d) 17-23 18 0.42 0.26~0.58 24 0~57 0.74  
 > 24 6 0.49 0.13~0.85 51 0~81   
Psychotherapy type CBT 16 0.47 0.29~0.65 46 2~70 0.08  
 IPT 9 0.14 -0.08~0.37 35 0~70   
 Other 16 0.41 0.24~0.59 36 0~65   
Format Individual 35 0.40 0.28~0.53 54 33~69 0.20  
 Group 6 0.15 -0.21~0.52 0 0~75   
Pharmacotherapy SSRI 14 0.18 0.01~0.35 61 30~78 0.01  
 TCA 12 0.38 0.17~0.60 0 0~58   
 Other 15 0.55 0.38~0.72 27 0~61   
Quality score 3-4 18 0.30 0.14~0.46 69 50~81 0.19  
 0-2 23 0.46 0.29~0.63 3 0~47   
 
Combined treatment vs psychotherapy e) 
       
Target group Adults in general 16 0.36 0.21~0.51 31 0~62 0.48  
 More specific 3 0.22 -0.13~0.58 38 0~81   
Psychotherapy type CBT 9 0.35 0.12~0.58 49 0~76 0.43  
 IPT 5 0.21 -0.05~0.47 0 0~79   
 Other 5 0.43 0.21~0.65 0 0~79   
Format Individual 15 0.36 0.22~0.51 42 0~68 0.36  
 Group 4 0.15 -0.27~0.58 0 0~85   
Pharmacotherapy SSRI 5 0.38 0.13~0.63 74 36~90 0.67  
 TCA 11 0.26 0.02~0.49 0 0~60   
 Other 3 0.40 0.14~0.66 35 0~79   
Quality score 3-4 7 0.32 0.11~0.52 41 0~75 0.78  
 0-2 12 0.36 0.16~0.56 31 0~65   
 
Combined treatment vs psychotherapy plus placebo 
      
Target group Adults in general 7 0.10 -0.17~0.37 59 5~82 0.22  
 More specific 10 0.31 0.10~0.52 0 0~62   
Baseline severity c) <17 2 0.17 -0.56~0.90 0 f) 0.62  
 17-23 2 -0.12 -0.92~0.68 85 f)   
 > 24 6 0.33 -0.11~0.76 56 0~82   
Psychotherapy type CBT 4 0.24 -0.13~0.60 51 0~84 0.86  
 IPT 3 0.31 -0.07~0.70 43 0~83   
 Other 10 0.19 -0.07~0.44 25 0~64   
Format Individual 13 0.18 -0.00~0.36 27 0~62 0.19  
 Group 4 0.46 0.08~0.84 15 0~87   
Pharmacotherapy g) SSRI 8 0.32 0.06~0.57 0 0~68 0.48  
 TCA 7 0.18 -0.12~0.47 60 7~82   
Quality score 3-4 6 0.25 -0.05~0.54 24 0~67 0.86  
 0-2 11 0.22 -0.01~0.44 35 0~68   
Abbreviations: CI: Confidence interval; Ncomp: number of comparisons; NNT: Numbers-needed-to-
treat. 
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Table 3 (continued). Effects of .combined treatment of adult depression compared with 
pharmacotherapy, psychotherapy, psychotherapy + placebo: Subgroup analyses a) b) . 
 
a) According to the random effects model. 
b) Because the comparison combined treatment versus placebo contained only 6 comparisons, no 
subgroup analyses were conducted. 
c) Only studies in which baseline severity according to the HAM-D-17 was reported, were included 
in these analyses. 
d) In one study the baseline score on the HAM-D was lower than 17 (Appleby et al., 1997); this 
study was not included in these analyses. 
e) The subgroup analyses on baseline severity were not conducted for this comparison, because in all 
studies, except one, baseline severity was moderate (17-23). 
f) When the number of studies is smaller than 3, the 95% CI can not be calculated. 
g) because only two studies were found in the category “other” these were not included in the 
analyses (Blom et al., 2007; Hernandez et al., 2004). 
 
Table 4. Standardized regression coefficients of characteristics of studies comparing 
combined treatment with pharmacotherapy, psychotherapy, and psychotherapy plus 
placebo: Multivariate metaregression analyses 
  
  Full model  Parsimonious model 
  Coef. 95% CI p  Coef 95% CI p 
Comparison vs pharmacotherapy Ref       
 vs placebo 0.19 -0.13~0.52      
 vs psychotherapy 0.02 -0.18~0.21      
 vs psychother + plac -0.10 -0.33~0.12      
         
Target group Adults vs specific -0.08 -0.26~0.10      
         
Baseline severity HAM-D (continuous) a) 0.03 -0.02~0.08      
         
Psychotherapy CBT Ref.       
 IPT -0.27 -0.49~-0.06 *  -0.19 -0.37~-0.02 * 
 Other therapy -0.13 -0.33~0.07      
         
Treatment format Individual versus group 0.03 -0.23~0.30      
         
Number of sessions (continuous) -0.00 -0.02~0.02      
         
Medication SSRI Ref.       
 TCA -0.03 -0.32~0.26      
 Other 0.20 -0.05~0.45      
         
Quality (continuous) -0.00 -0.08~0.07      
         
Constant  0.50 0.08~0.92 *  0.39 0.30~0.48 ** 
*: p<0.05; **: p<0.001 
  
a) Because not all studies reported baseline severity according to the HAM-D, we conducted a 
separate metaregression analysis for the studies in which baseline HAM-D was reported. The 
coefficient reported here is the result of this separate analysis. 
 
 
 
 
 
 
 
Articles Section  
 
Combined Treatment of Adult Depression 159 
Because all comparisons included a combined treatment (compared with 
another treatment), we conducted a multivariate metaregression analyses in which 
we included all comparisons, as well as the basic characteristics of the studies that 
were examined in the moderator analysis. In order to avoid collinearity, we first 
calculated the correlation between the characteristics of the studies that were 
meant to be entered into the regression model. Because we found no correlation 
higher than r = 0.50, we decided to include all variables in the model. Then we 
conducted a multivariate metaregression analysis, with the effect size as the 
dependent variable, and the comparisons as well as the other characteristics of the 
studies, participants, and interventions as predictors (Table 4). As can be seen in 
Table 4, none of the predictors was significantly associated with the effect size, 
except for the variable indicating that IPT was used as psychotherapy (compared 
with other therapies). IPT seemed to be associated with a smaller difference 
between combined treatment and the comparison groups. 
We then conducted a (manual) back-step metaregression analysis. In this 
analysis, we dropped the least significant variable in each step, until only 
significant predictors were retained in the model (Table 4). The results of this 
parsimonious model also only indicated that IPT as psychotherapy was 
significantly associated with the effect size (p < 0.05). 
Because baseline severity according to the HAM-D was not included in 
all studies, we conducted a separate meta-analysis with the studies in which 
baseline severity was reported (N=32). As can be seen in Table 4, we did not find 
that baseline severity was associated with the effect size. 
  
Discussion 
  
This was the first comprehensive meta-analysis of combined 
pharmacotherapy and psychotherapy for adult depression covering several 
comparisons and placebo alone. Although we found only a small number of 
studies comparing combined treatment against pill placebo, the results of these 
studies showed that combined treatment had a moderate effect size on depressive 
symptomatology. The resulting effect size (g = 0.46) was considerably larger than 
the effect sizes found for pharmacotherapy for depression compared with placebo 
(g = 0.31; Turner, Matthews, Linardatos, Tell, & Rosenthal, 2008) and larger than 
the effect sizes found for psychotherapy versus pill placebo (g = 0.25; Cuijpers et 
al., 2014). This suggests that combined treatment is superior to single treatments 
when compared against pill placebo within the same trials. However, this should 
be interpreted with caution, because the confidence interval around the effect size 
for combined treatment versus placebo were broad as a result of the small number 
of studies. Furthermore, there were some indications for publication bias and after 
adjustment for this bias, the effect size was considerably smaller. 
We could also confirm in this meta-analysis that combined treatment is 
significantly more effective than pharmacotherapy alone, than psychotherapy 
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alone, and even against psychotherapy plus placebo. For each of these 
comparisons several dozens of comparisons were available. These results were in 
line with earlier meta-analyses examining each of these comparisons (De Maat et 
al., 2007; Cuijpers et al., 2014; Pampanolla et al., 2004). 
In the multivariate metaregression, in which we included all comparisons 
simultaneously, we did not find that the effect size for combined treatment versus 
placebo was significantly higher than combined versus pharmacotherapy, or 
combined versus psychotherapy (with or without placebo). So, although the 
effects for combined versus placebo were larger than for the other comparisons, 
this was not significant. However, this can very well be caused by the broad 
confidence intervals around the effect size for combined treatment versus placebo. 
An unexpected finding was that IPT seemed to result in lower effect sizes 
than CBT and other psychotherapies. This is unexpected as earlier meta-analyses 
found that IPT may be somewhat more effective than other psychotherapies 
(Cuijpers, van Straten, Andersson, & van Oppen, 2008; Barth, Munder, Gerger, 
Nuesch, Trelle, Znoj, et al., 2013). However, this finding should be considered 
with caution because it is not the result of direct comparisons with other therapies, 
which would provide much stronger evidence. Furthermore, it may very well be 
that this finding is caused by a third variable associated with both the effect size 
and this particular characteristic, but that was not examined in the metaregression 
analysis. 
From a clinical point of view the results of this meta-analysis raise many 
questions. First, in regular care it is often the case that medication and 
psychotherapy is provided by different clinicians and sometimes even at different 
clinics, with antidepressant medication often being prescribed in primary care and 
psychotherapy delivered in secondary care or settings outside of the hospital. 
Moreover, funding of services differs across countries as well with different 
structures for medication and psychotherapy. Second, we cannot exclude the 
possibility that different medications and different psychotherapies work more or 
less well together. In this meta-analysis many studies used CBT, but even within 
CBT there are differences with more or less emphasis on behavioral and cognitive 
aspects. Third, we did not cover the costs of treatment in this meta-analysis as it is 
obvious that two simultanous treatments cost more than one. The NNTs give 
some indications here but perhaps the most important clinical implication for 
caregivers is that it may be worthwhile to add medication to psychotherapy and 
vice versa. From a stepped care perspective, augmenting treatment components 
might be especially helpful when initial monotherapy does not lead to a rapid 
response. Sequenced treatment approaches, in which additional treatment is only 
provided when it is needed or when it is known to improve long-term outcomes, 
might prove to offer a better risk/benefit ratio in the long-term (Forand, DeRubeis 
& Amsterdam 2013).  
In addition to the added value of psychotherapy to medication, there is 
preliminary evidence that psychotherapy has longer term effects than medication 
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even when staying on the medication (Cuijpers, Hollon, Van Straten, Bockting, 
Berking, & Andersson, 2013). If this is the case when psychotherapy is provided 
together with medication as well is not yet known and will require more studies 
and longer term outcomes. A final clinical implication has to do with severity as 
there are still many unknowns regarding response rates for different subgroups. 
As mentioned earlier in this paper a previous meta-analysis showed smaller 
effects of psychotherapy for dysthymia and chronic depression (Cuijpers, et al., 
2010), and it is likely that the moderating effect of chronicity cannot be detected 
by means of cut-off scores only done in this meta-analysis.  
The results of this meta-analysis should be considered with caution 
because of its limitations. First, the number of studies comparing combined 
treatment with placebo was small. Second, the quality of many of the included 
studies was not optimal, although we did not find indications that the quality was 
associated with the effect sizes. However, not finding such associations does not 
automatically imply that it does not exist, especially when the number of studies 
is small, which was the case here.  
Despite these limitations, we can conclude that combined treatment of 
depression may be the best treatment available for adult depression, and that it is 
significantly more effective than placebo, pharmacotherapy, psychotherapy and 
the combination of psychotherapy and placebo. 
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